The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VTYX | +198.64% | N/A | N/A | -69% |
| S&P | +14.5% | +93.32% | +14.09% | +47% |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.32M | -2.2% |
| Market Cap | $152.29M | -6.5% |
| Market Cap / Employee | $1.86M | 0.0% |
| Employees | 82 | 2.5% |
| Net Income | -$26.99M | 15.5% |
| EBITDA | -$29.01M | 18.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.30M | -21.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.16M | -11.0% |
| Short Term Debt | $1.14M | 17.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.15% | 7.9% |
| Return On Invested Capital | -6.17% | -317.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.32M | 13.3% |
| Operating Free Cash Flow | -$21.28M | 13.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.55 | 0.56 | 0.32 | 0.66 | 23.94% |
| Price to Tangible Book Value | 0.55 | 0.56 | 0.32 | 0.66 | 23.94% |
| Enterprise Value to EBITDA | 2.87 | 1.62 | 4.59 | 1.60 | -13.35% |
| Return on Equity | -54.2% | -54.3% | -46.0% | -48.6% | -13.73% |
| Total Debt | $11.04M | $10.79M | $10.55M | $10.30M | -8.61% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
